Related Experiment Video

Updated: Apr 5, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas

Antònia Obrador-Hevia1,2, Esther Martinez-Font1, Irene Felipe-Abrio3

  • 1a 1 Group of Advanced Therapies and Biomarkers in Clinical Oncology , Institut d'Investigació Sanitària de Palma (IdISPa) , Palma de Mallorca, Spain.

Cancer Investigation
|August 20, 2015
PubMed

Insights

MDM2 inhibitors, like RG7112, can enhance Trabectedin treatment efficacy in liposarcoma. This combination therapy shows promise for treating sarcomas with MDM2 amplification.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • MDM2 is a key negative regulator of the p53 tumor suppressor.
  • Trabectedin is a second-line treatment for certain sarcomas, inducing DNA damage and p53-dependent apoptosis.
  • MDM2 amplification can affect treatment response in sarcomas.

Purpose of the Study:

  • To investigate the potential of combining MDM2 inhibitors with Trabectedin.
  • To evaluate this combination therapy in soft tissue sarcoma models.
  • To identify specific sarcoma subtypes that may benefit from this approach.

Main Methods:

  • In vitro assessment of Trabectedin, Nutlin-3A, and RG7112 as single agents and in combination.
  • Evaluation of antitumor effects in sarcoma cell lines.
  • Focus on MDM2-amplified liposarcoma models.

Main Results:

  • RG7112 demonstrated significant synergy with Trabectedin in MDM2-amplified liposarcoma cells.
  • The combination therapy showed enhanced antitumor effects compared to single agents.
  • Nutlin-3A also showed potential, though RG7112 exhibited stronger synergy.

Conclusions:

  • Combining MDM2 inhibitors with Trabectedin is a promising therapeutic strategy for sarcomas.
  • This approach is particularly relevant for sarcomas with MDM2 amplification.
  • Further clinical investigation is warranted to validate these findings in sarcoma patients.
Keywords:
LiposarcomaMDM2RG7112Soft tissue sarcomasTrabectedin

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.3K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K